Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.53. Xtant Medical shares last traded at $0.52, with a volume of 94,800 shares traded.
Analyst Upgrades and Downgrades
Separately, Craig Hallum set a $1.50 target price on Xtant Medical and gave the stock a "buy" rating in a report on Friday, October 18th.
Get Our Latest Stock Analysis on Xtant Medical
Xtant Medical Stock Performance
The stock has a market cap of $70.37 million, a PE ratio of -25.94 and a beta of 0.39. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.44 and a quick ratio of 1.01.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Juniper Investment Company LLC acquired a new stake in Xtant Medical during the first quarter worth about $408,000. Vanguard Group Inc. grew its holdings in Xtant Medical by 3.2% during the first quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company's stock worth $1,812,000 after acquiring an additional 48,319 shares during the period. Finally, Evernest Financial Advisors LLC acquired a new stake in Xtant Medical during the third quarter worth about $27,000. 69.33% of the stock is owned by institutional investors and hedge funds.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Featured Articles
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
